Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction? Results from a prospective multicentre study

Internal Medicine Journal

Volumn 38, Issue 11, 2008, Pages 845-851

  Tobing, D ^a   French, J ^a,c   Varigos, J ^b   Meehan, A ^b   Billah, B ^b   Krum, H ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

Angiography; Angioplasty; Congestive heart failure; Invasive procedure; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ST SEGMENT ELEVATION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; ANTIFIBRINOLYTIC AGENTS; CORONARY ANGIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 57649219145     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01594.x     Document Type: Article

References (37)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 1 : 397 402.
2. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990 336 : 65 71.
3. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990 336 : 71 5.
4. Kashani A, Giugliano RP, Antman EM, Morrow DA, Gibson CM, Murphy SA et al. Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur Heart J 2004 25 : 1702 10.
5. Rott D, Behar S, Gottlieb S, Boyko V, Hod H. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s. Am J Cardiol 1997 80 : 859 64.
6. Miller WL, Wright RS, Grill JP, Kopecky SL. Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin Cardiol 2000 23 : 751 8.
7. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005 294 : 448 54.
8. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont M-C, Lopez-Zendon Z et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004 109 : 494 9.
9. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J 1996 312 : 1637 41.
10. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002 40 : 1389 94.
11. DeGeare VS, Boura JA, Grines LL et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2001 87 : 1035 8.
12. Stenestrand U, Wallentin L. Early revascularization and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet 2002 359 : 1805 11.
13. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001 285 : 190 92.
14. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 110 : e82 e293.
15. Van de Werf FJ, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003 24 : 28 66.
16. Wallentin L, Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial: FRISC II Investigators: fast revascularization during instability in coronary artery disease. Lancet 2000 356 : 9 16.
17. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001 344 : 1879 87.
18. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial: Randomized Intervention Trial of unstable Angina. Lancet 2002 360 : 743 51.
19. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000 355 : 1575 81.
20. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 357 : 1385 90.
21. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 : 1309 21.
22. Krum H, Meehan A, Varigos J, Loane PR, Billah B. Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multi centre study. Med J Aust 2006 185 : 191 4.
23. Remme WJ, Swedberg K, The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001 22 : 1527 60.
24. French JK, Williams B, Hart H, Woo K, Wang L, Grant J et al. Management of acute myocardial infarction in Auckland. N Z Med J 1996 108 : 248 51.
25. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK et al. 2007 focussed update of the ACC/AHA 2004 Guidelines for the Management of patients with ST Elevation Myocardial Infarction. A report of the American College of Cardiology/American Heart Association Taskforce on Proactive Guidelines. In press.
26. Rott D, Behar S, Leor J, Hod H, Boyko V, Mandelzweig L et al. for the Working Group on Intensive Cardiac Care, Israel Heart society. Effect on survival of acute myocardial infarction in Killip Classes II or III patients undergoing invasive coronary procedures. Am J Cardiol 2001 88 : 618 23.
27. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M et al. Management of elderly patients with congestive heart failure - design of the Trial of Intensified versus Standard Medical Therapy in Elderly patients with Congestive Heart Failure (TIME-CCHF). Am Heart J 2006 151 : 949 55.
28. Sabatine MS, Canon CP, Gibson CM, López-Sendón JL, Montalesco G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 352 : 1179 89.
29. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005 366 : 1607 21.
30. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M et al. for the CURE trial investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003 107 : 966 72.
31. Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luïjten HE, Hertzberger DP et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT)-2 trial. Circulation 2002 106 : 659 65.
32. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002 347 : 969 74.
33. van Es RF, Jonker JJC, Verheught FWA et al. for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 2002 360 : 109 13.
34. Richardson J, Truman C. An audit of discharge medication for secondary prophylaxis post myocardial infarction. J Clin Pharm Ther 1996 21 : 413 16.
35. Merle L, Laroche ML, Dantoine T, Charmes JP. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005 22 : 375 92.
36. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005 95 : 896 8.
37. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003 146 : 848 53.